CL2020002505A1 - Una combinación farmacéutica triple que comprende dabrafenib, trametinib y un inhibidor de erk - Google Patents
Una combinación farmacéutica triple que comprende dabrafenib, trametinib y un inhibidor de erkInfo
- Publication number
- CL2020002505A1 CL2020002505A1 CL2020002505A CL2020002505A CL2020002505A1 CL 2020002505 A1 CL2020002505 A1 CL 2020002505A1 CL 2020002505 A CL2020002505 A CL 2020002505A CL 2020002505 A CL2020002505 A CL 2020002505A CL 2020002505 A1 CL2020002505 A1 CL 2020002505A1
- Authority
- CL
- Chile
- Prior art keywords
- dabrafenib
- trametinib
- pharmaceutical combination
- erk inhibitor
- triple
- Prior art date
Links
- 239000012824 ERK inhibitor Substances 0.000 title abstract 2
- 229960002465 dabrafenib Drugs 0.000 title abstract 2
- BFSMGDJOXZAERB-UHFFFAOYSA-N dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 title abstract 2
- 229960004066 trametinib Drugs 0.000 title abstract 2
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 title abstract 2
- 102000043136 MAP kinase family Human genes 0.000 abstract 1
- 108091054455 MAP kinase family Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000037361 pathway Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862650744P | 2018-03-30 | 2018-03-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2020002505A1 true CL2020002505A1 (es) | 2021-03-05 |
Family
ID=66397350
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2020002505A CL2020002505A1 (es) | 2018-03-30 | 2020-09-28 | Una combinación farmacéutica triple que comprende dabrafenib, trametinib y un inhibidor de erk |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20210121460A1 (https=) |
| EP (1) | EP3773586A1 (https=) |
| JP (1) | JP2021519285A (https=) |
| KR (1) | KR20200138303A (https=) |
| CN (1) | CN111936141A (https=) |
| AU (1) | AU2019246719B2 (https=) |
| BR (1) | BR112020019577A2 (https=) |
| CA (1) | CA3094780A1 (https=) |
| CL (1) | CL2020002505A1 (https=) |
| IL (1) | IL277380A (https=) |
| MX (1) | MX2020010231A (https=) |
| RU (1) | RU2020135055A (https=) |
| WO (1) | WO2019186488A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4110341A2 (en) * | 2020-02-28 | 2023-01-04 | Novartis AG | A triple pharmaceutical combination comprising dabrafenib, an erk inhibitor and a raf inhibitor |
| EP4110338A1 (en) * | 2020-02-28 | 2023-01-04 | Novartis AG | A triple pharmaceutical combination comprising dabrafenib, an erk inhibitor and a shp2 inhibitor |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1761528T1 (sl) | 2004-06-11 | 2008-06-30 | Japan Tobacco Inc | 5-amino-2,4,7-triokso-3,4,7,8-tetrahidro-2H-pirido(2,3-D)pirimidinski derivati in sorodne spojine za zdravljenje raka |
| UA103319C2 (en) | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
| AP2016009099A0 (en) * | 2013-11-01 | 2016-03-31 | Novartis Ag | Aminoheteroaryl benzamides as kinase inhibitors |
| PL3319993T3 (pl) * | 2015-07-10 | 2020-07-27 | Genmab A/S | Specyficzne wobec AXL koniugaty przeciwciało-lek do leczenia raka |
| AU2017329090B9 (en) * | 2016-09-19 | 2019-09-05 | Novartis Ag | Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor |
-
2019
- 2019-03-29 MX MX2020010231A patent/MX2020010231A/es unknown
- 2019-03-29 WO PCT/IB2019/052601 patent/WO2019186488A1/en not_active Ceased
- 2019-03-29 RU RU2020135055A patent/RU2020135055A/ru unknown
- 2019-03-29 EP EP19721810.0A patent/EP3773586A1/en not_active Withdrawn
- 2019-03-29 BR BR112020019577-4A patent/BR112020019577A2/pt not_active Application Discontinuation
- 2019-03-29 AU AU2019246719A patent/AU2019246719B2/en not_active Ceased
- 2019-03-29 US US17/042,591 patent/US20210121460A1/en not_active Abandoned
- 2019-03-29 KR KR1020207030757A patent/KR20200138303A/ko not_active Withdrawn
- 2019-03-29 JP JP2020551481A patent/JP2021519285A/ja active Pending
- 2019-03-29 CN CN201980021573.3A patent/CN111936141A/zh active Pending
- 2019-03-29 CA CA3094780A patent/CA3094780A1/en active Pending
-
2020
- 2020-09-15 IL IL277380A patent/IL277380A/en unknown
- 2020-09-28 CL CL2020002505A patent/CL2020002505A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021519285A (ja) | 2021-08-10 |
| EP3773586A1 (en) | 2021-02-17 |
| MX2020010231A (es) | 2020-10-28 |
| AU2019246719B2 (en) | 2022-06-16 |
| IL277380A (en) | 2020-11-30 |
| WO2019186488A1 (en) | 2019-10-03 |
| AU2019246719A1 (en) | 2020-10-01 |
| CA3094780A1 (en) | 2019-10-03 |
| RU2020135055A (ru) | 2022-05-05 |
| BR112020019577A2 (pt) | 2021-01-05 |
| US20210121460A1 (en) | 2021-04-29 |
| KR20200138303A (ko) | 2020-12-09 |
| CN111936141A (zh) | 2020-11-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021002099A1 (es) | Combinación farmacéutica que comprende tno155 y ribociclib. | |
| CL2020002032A1 (es) | Cristal de un compuesto derivado de 7,8-difluoro-6,11-dihidrodibenzotiepina, composición farmacéutica, útil en reducir el tiempo de alivio de los síntomas de la influenza para tratar y/o prevenir una infección provocada por el virus de la influenza. (divisional solicitud 201900325). | |
| CL2021001292A1 (es) | Terapia de combinación que incluye un inhibidor de krasg12c y uno o más agentes farmacéuticamente activos adicionales para el tratamiento de cánceres | |
| CO2019001212A2 (es) | Composiciones y métodos de inhibición del masp-3 para el tratamiento de diversas enfermedades y trastornos | |
| CO2019007839A2 (es) | Composiciones y métodos para inhibir la acción de la arginasa | |
| CL2020001742A1 (es) | Inhibidores de glicolato oxidasa para el tratamiento de enfermedades | |
| CO2021001472A2 (es) | Inhibidores de transglutaminasa 2 (tg2) | |
| MX2019009853A (es) | Terapia de combinacion que incluye un inhibidor mdm2 y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres. | |
| MX2017006832A (es) | Derivados de ácido biliar como agonistas de fxr/tgr5 y métodos para el uso de los mismos. | |
| EA201790170A1 (ru) | Терапевтические соединения-ингибиторы | |
| CR20160308A (es) | Combinaciones de inhibidores de histona deacetilasa y farmacos inmunomoduladores | |
| EA201692437A1 (ru) | Комбинация | |
| MX2019001011A (es) | Compuestos farmaceuticos. | |
| MX391217B (es) | Moduladores de rodopsina p23h con especificidad de alelo. | |
| CL2019002557A1 (es) | Pirimidopirimidinonas útiles como inhibidores de la quinasa wee-1. | |
| MX2022013081A (es) | Compuestos para el tratamiento de sars. | |
| CL2018000688A1 (es) | Compuestos heterociclicos que contienen bencilamina y composiciones útiles contra infección por micobacterias | |
| MX2017011000A (es) | Compuestos de pirazol sustituidos como inhibidores de serina proteasa. | |
| ECSP22044525A (es) | Terapia de combinaci?n que comprende un inhibidor de alk2 y un inhibidor de jak2 | |
| CO2021004934A2 (es) | Composiciones y métodos para tratar retinitis pigmentosa | |
| CO2018013020A2 (es) | Combinaciones farmacéuticas para el tratamiento del cáncer | |
| MX2017009246A (es) | Farmaco de combinacion. | |
| MX2017011018A (es) | Inhibicion de la actividad de olig2. | |
| CL2021000018A1 (es) | Oligonucleótidos para modular la expresión de rtel1 | |
| CL2020002505A1 (es) | Una combinación farmacéutica triple que comprende dabrafenib, trametinib y un inhibidor de erk |